%0 Journal Article
%T Curative Therapies for Sickle Cell Disease
%A Deeksha Katoch
%A Kirshma Khemani
%A Lakshmanan Krishnamurti
%J Archive of "The Ochsner Journal".
%D 2019
%R 10.31486/toj.18.0044
%X Background: Sickle cell disease (SCD) is an inherited hemoglobinopathy associated with severe morbidity, impaired quality of life, and premature mortality. Hematopoietic stem cell transplantation (HSCT) is the only curative treatment available for patients with SCD and has a >90% event-free survival when a matched related donor is used. However, availability of human leukocyte antigen (HLA)¨Cidentical sibling donors for the SCD population is limited. The use of HLA-matched unrelated donors or related haploidentical donors has the potential to expand the donor pool
%K Anemia¨Csickle cell
%K bone marrow transplantation
%K genetic therapy
%K stem cell transplantation
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584191/